FY2025 · ended Dec 31, 2025 · Revenue $189.76M, +45.8% YoY · Filed Feb 26, 2026
Rhythm Pharmaceuticals, Inc. (RYTM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $189.8 million and a net loss of $196.5 million. Free cash flow was -$116.6 million. As of Sep 30, 2026 it held $320.9 million in cash and investments and $106.2 million in total debt.
Revenue (TTM)
$280.75M
+61.0% vs year-ago TTM
Net income (TTM)
$-193.81M
-0.8% vs year-ago TTM
Operating cash flow (TTM)
$-81.79M
+25.1% vs year-ago TTM
Free cash flow
$-116.63M
+14.4% vs prior year
EPS (TTM)
$-2.91
+6.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
68.29M
+8.0% vs prior year
Net cash
$214.76M
as of Sep 30, 2026
Operating margin
-66.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RYTM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1649904
- Former names
- RHYTHM METABOLIC, INC. (until Aug 12, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $189.8M | $130.1M | $77.4M | $23.6M | $3.2M |
| Operating income | -$192.0M | -$265.5M | -$184.4M | -$179.2M | -$170.1M |
| Net income | -$196.5M | -$260.6M | -$184.7M | -$181.1M | -$69.6M |
| Diluted EPS | -$3.11 | -$4.34 | -$3.20 | -$3.47 | -$1.40 |
| Operating cash flow | -$115.7M | -$113.9M | -$136.2M | -$173.4M | -$146.0M |
| Free cash flow | -$116.6M | — | -$136.2M | -$173.7M | -$146.4M |
| Total assets | $480.2M | $392.3M | $332.7M | $382.5M | $329.5M |
| Total liabilities | $210.2M | $227.7M | $163.0M | $118.2M | $45.4M |
| Stockholders' equity | $139.1M | $21.7M | $169.8M | $264.3M | $284.2M |
| Cash and investments | $388.9M | $320.6M | $275.8M | $333.3M | $294.9M |
| Total debt | $112.2M | $113.7M | $1.3M | $1.9M | $4.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 13, 2026 |
All 837 Rhythm Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.